ZUG, Switzerland, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic ...

A nationwide cohort study of more than 4 million adults showed that people with allergic diseases were nearly one third more likely to develop optic neuritis than those without such conditions, with ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Fampridine resulted in no significant observed ...

Please provide your email address to receive an email when new articles are posted on . Being male or aged older than 40 years were consistently associated with poorer acute optic neuritis outcomes.

Sungkyunkwan University researchers in Korea ran a nationwide cohort analysis linking allergic diseases to increased optic neuritis risk, with allergic rhinitis showing the strongest association.

Erythropoietin (EPO), shown in early studies to potentially provide neuroprotection for patients with optic neuritis, failed to provide any significant neuroprotection in comparison with placebo in a ...

Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic diseases with significant unmet medical needs, today ...